Verici Dx Plc (VRCI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verici Dx Plc (VRCI) has a cash flow conversion efficiency ratio of -1.091x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.71 Million ≈ $-329.35 USD) by net assets (GBX2.48 Million ≈ $301.99 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Verici Dx Plc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Verici Dx Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Verici Dx Plc carry for a breakdown of total debt and financial obligations.
Verici Dx Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verici Dx Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xtract Resources PLC
LSE:XTR
|
-0.023x |
|
BLOCKMATE VENTURES INC.
F:8MH
|
0.073x |
|
Northamber PLC
LSE:NAR
|
0.110x |
|
Spearmint Resources Inc
F:SQH
|
-0.025x |
|
Abacus Global Management, Inc.
NASDAQ:ABX
|
-0.075x |
|
NEW FRONTIER VENT. INC.
F:S1O
|
N/A |
|
XTC Lithium Limited
AU:XTC
|
-0.140x |
|
Cel AI PLC
LSE:CLAI
|
-0.749x |
Annual Cash Flow Conversion Efficiency for Verici Dx Plc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Verici Dx Plc from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Verici Dx Plc (VRCI) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX5.26 Million ≈ $640.60 |
GBX-6.02 Million ≈ $-732.46 |
-1.143x | +43.18% |
| 2023-12-31 | GBX3.56 Million ≈ $432.91 |
GBX-7.16 Million ≈ $-871.16 |
-2.012x | -130.04% |
| 2022-12-31 | GBX11.51 Million ≈ $1.40K |
GBX-10.07 Million ≈ $-1.22K |
-0.875x | -65.46% |
| 2021-12-31 | GBX11.98 Million ≈ $1.46K |
GBX-6.34 Million ≈ $-770.96 |
-0.529x | -709.63% |
| 2020-12-31 | GBX19.62 Million ≈ $2.39K |
GBX-1.28 Million ≈ $-155.92 |
-0.065x | -- |
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more